Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-04-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司调整募投项目内部投资结构的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the adjustment of the internal investment structure of fundraising projects by Hangzhou Anjiesi Medical Technology Co., Ltd. It includes specifics about the fundraising amount, project investment details, adjustments to the internal investment structure, reasons for adjustments, and approvals by the board and supervisory committee. The document references regulatory compliance and approvals but does not contain financial statements or quarterly/yearly financial results. It is not an announcement of a report but a formal verification opinion related to fundraising project adjustments. This fits best under Capital/Financing Update (CAP) as it deals with the use and adjustment of raised capital funds and investment structure changes within fundraising projects.
2025-04-22 Chinese
天健审〔2025〕5890号-安杰思2024年年度内控报告.pdf
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report." It includes an audit opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2024. The document is issued by a certified public accounting firm and includes supporting attachments such as business licenses and CPA certificates. The content focuses on the audit of internal controls rather than the full annual report or financial statements. The document length is 3848 characters, which is relatively short but contains the full audit report on internal controls, not just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR) rather than an Annual Report (10-K) or Regulatory Filing (RNS). FY 2024
2025-04-22 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司2024年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. acting as the sponsor for Hangzhou Anjiesi Medical Technology Co., Ltd. It focuses on the 2024 annual special inspection opinion regarding the deposit and use of raised funds from the company's initial public offering (IPO) on the STAR Market. The document includes specifics about the amount raised, timing, usage, management, and compliance with regulatory requirements. It also contains detailed tables showing the use of funds, project progress, and board meeting approvals related to fund usage. The document is not a general annual report or earnings release but a specialized audit or inspection report on the use of IPO proceeds. It references regulatory rules and includes an auditor's verification report. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on the use of raised funds, not a full annual report or other category. The document length (8016 characters) and content confirm it is the report itself, not just an announcement or certification letter. FY 2024
2025-04-22 Chinese
安杰思第二届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board (监事会) of Hangzhou Anjiesi Medical Technology Co., Ltd. It includes multiple agenda items such as approval of the 2024 Supervisory Board Work Report, 2024 fundraising usage report, internal control evaluation report, profit distribution plan, financial statements audited by an accounting firm, remuneration plans, stock incentive plans, employee stock ownership plans, and approval of the 2024 Annual Report and 2025 Q1 Report. The document is a formal meeting resolution announcement, not the reports themselves. It references that the full reports are disclosed separately on the Shanghai Stock Exchange website with specific announcement numbers. The document length is about 5896 characters, which is relatively short for containing full financial statements or detailed reports. Therefore, this document is an official announcement of Supervisory Board meeting resolutions, including approval of various reports and plans, but not the reports themselves. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement of meeting resolutions and approvals, not the actual Annual Report (10-K) or Interim Report (IR).
2025-04-22 Chinese
安杰思独立董事提名人声明与承诺-冯洋
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for a listed company on the Science and Technology Innovation Board (科创板). It details the qualifications, legal compliance, independence criteria, and absence of adverse records for the nominee. The content is focused on governance and compliance related to board nominations rather than financial results, audit, or shareholder voting outcomes. It does not contain financial data, earnings, or report publication announcements. The document fits best under Board/Management Information (MANG) as it concerns the nomination and qualifications of a board member candidate.
2025-04-22 Chinese
安杰思2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024 Annual Special Report on the Deposit and Actual Use of Raised Funds" by Hangzhou Anjiesi Medical Technology Co., Ltd. It details the amount of funds raised through an IPO, the management and use of these funds, including cash management, investment projects, and compliance with regulatory requirements. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document includes detailed financial data on the raised funds, their usage, balances, and investment projects, as well as auditor and sponsor opinions on the compliance and accuracy of the report. This is a specialized report focused on the management and use of capital raised by the company, not a full annual report or earnings release. It is a detailed report on capital raising and fund usage, which fits the category of Capital/Financing Update (CAP). The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2025-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.